Annual Biomarkers Congress

Osaka, Japan   September 20-21, 2018

Call for Abstract

A Biomarkers is an appropriate that can be equitably measured and assess as an indicator of a physiological as well as a pathological progress or pharmacological response to a therapeutic intervention. Classical biomarkers are quantitative alteration in blood pressure; blood lactate levels consecutive exercises, and blood glucose in diabetes mellitus. A biomarker, or bio indicator, for the most part alludes to a quantifiable pointer of some organic state or condition. The term is additionally infrequently used to allude to a substance the nearness of which demonstrates the presence of a living being. Environmental Assessment also carried out in the natural or synthetic form as biomonitoring. Encourage, life structures, life events for Interim analysis. Biomarkers are regularly measured and assessed to look at ordinary natural procedures, pathogenic procedures, or pharmacologic reactions to a restorative mediation.

  • Track 1-1: Biomarkers in drug development
  • Track 1-2: Enzyme markers
  • Track 1-3: Biomarkers instrumentation
  • Track 1-4: Advantages and disadvantages of biomarkers
  • Track 1-5: Marine and fresh water biomarkers

Clinical medicine as Biomarkers has been used for decades. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention Any specific molecular conversion of a cell on DNA, RNA, metabolite, or protein level can be referred to as Molecular biomarkers .The fuse of biomarker in clinical trials for different illness conditions will advance a certain indicative and remedial approach using even the medicinal gadgets to recognize clinical biomarkers. Right now, this is the trending business.

  • Track 2-1: Molecular biomarkers
  • Track 2-2: Genomic biomarkers
  • Track 2-3: Transcriptomic biomarkers
  • Track 2-4: Proteomic biomarkers
  • Track 2-5: Metabolic biomarkers

The indicative process of the presence of cancer in the body is referred as cancer biomarkers. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. There are different of cancer where biomarkers have it application such as lung, Melanoma, breast, Colorectal, Pancreas and many more. Biochemically, cancer biomarkers can be DNA (germline or somatic), RNA, proteins, peptides, hormones, metabolites, and even biological processes such as apoptosis, angiogenesis or proliferation. There are three major types of cancer biomarkers based on their clinical use: prognostic, predictive, and pharmacodynamic markers.

  • Track 3-1: Biomarkers: cancer
  • Track 3-2: Genomic Biomarkers in Oncology
  • Track 3-3: Advanced Diagnostic Tools for Analyzing the Cancer Genome
  • Track 3-4: Breast cancer: novel biomarkers in the continuum of breast cancer
  • Track 3-5: Tumor microenvironment
  • Track 3-6: Cancer biomarkers in body fluid
  • Track 3-7: Ovarian biomarkers
  • Track 3-8: Other cancer biomarkers

A biomarker is a distinctive that can be equitably measured as an indicator of commonly biological processes, pathogenic processes or a pharmacological response to a therapeutic intervention. Biomarkers can be used for many purposes including disease diagnosis and prognosis, prediction and assessment of treatment response. Also, Biomarkers are used as an indicator of a biological factor that represents either a subclinical manifestation, stage of the disorder, or a surrogate manifestation of the disease. The potential uses of this class of biomarkers include, firstly as identification of individuals destined to become affected or who are in the “preclinical” stages of the illness, secondly, reduction in disease heterogeneity in clinical trials or epidemiologic studies, third, reflection of the natural history of disease encompassing the phases of induction, latency and detection, and finally, target for a clinical trial.

  • Track 4-1: Biomarkers for Alzheimers
  • Track 4-2: Biomarkers for Cardiovascular diseases
  • Track 4-3: Biomarkers for Neurodegenerative diseases
  • Track 4-4: Biomarkers for Diabetes
  • Track 4-5: Biomarkers for Huntington diseases
  • Track 4-6: Biomarkers for Behcets disease
  • Track 4-7: Biomarkers for other diseases

Those putative biomarkers for Disease diagnosis and prognosis the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility. The Food and Drug Administration has approved few biomarkers due to its advanced technology. The practical application of each protein separation or identification technique is analyzed using specific examples, Including four major application of immunology as ELISA, FACS, Western Blot and Immunoprecipitation. Mass spectrometers are unique which can directly analyze any biological molecule likely to be influenced to ionization. The biological studies of human metabolites and proteins using recent mass spectrometry technology (metabolomics and proteomics, respectively) have been ongoing for over a decade.

  • Track 5-1: Mass Spectrometry techniques
  • Track 5-2: Based Lipidomic for Biomarker Research
  • Track 5-3: Immunological techniques.
  • Track 5-4: Biomarkers techniques for other diseases

The major uses of biomarkers in clinical investigation are in the form of clinical trials and monitoring. The entire spectrum of disease from the earliest indication to the terminal stages resonate biomarkers. Field studies of biomarkers is generally done on the environmental assessment based on aquatic contamination by seeing the aqua life or by understanding the normal habitat change of different organism .biomarkers also shows the best relationships between its response when compared to the health /ecological effect. It provides variety of human and animal materials principally through immuno-assays and quantitative PCR can be analytically determined at Biomarker Laboratory.

  • Track 6-1: Experimental objective
  • Track 6-2: Relationship between exposure and biomarkers responses
  • Track 6-3: Relationship between biomarkers responses and health/ecological effects

A biologic aspect or biomarker detectable in an image is being termed as imaging biomarkers. The most valuable sources of data in evidence-based medicine are to be known as clinical trials. As Instrumentation, it involves different tools and techniques such as, CT, MRI, PET and ultrasonography biomarkers which are broadly used in cancer research and drug development. As medical imaging has made advanced technologies, older corresponding techniques have been repeatedly exchanged with newer digital methods of image acquisition, processing, archiving, and display. This evolution has occurred in parallel with advancements in our understanding of the molecular underpinnings of disease and the rise of a more statistical and evidence-based approach to diagnosis and treatment.

  • Track 7-1: Positron Emission Tomography (PET)
  • Track 7-2: Molecular Probe imaging (MPI)
  • Track 7-3: Magnetic resonance imaging (MRI)
  • Track 7-4: Ultrasonography
  • Track 7-5: Computed tomography(CT)
  • Track 7-6: Other advance imaging instrumentation

To all aspects of biomarkers that relate to chemical exposure and their effects on biological systems is a commonly referred as biomarkers in toxicology. Both vertebrate and non-vertebrate species models for toxicological testing and development of biomarkers are being used for recent research. The study of the harmful effects of various chemical, biological and physical agents on living organisms with a multidisciplinary field of science concerned also known as ecotox or environmental toxicology.

  • Track 8-1: Genotoxicity biomarkers
  • Track 8-2: Aquatic bio indicators and bio monitoring
  • Track 8-3: Environmental toxicology
  • Track 8-4: Liver Toxicity
  • Track 8-5: Status of biomarkers for predicting toxicity

Any biological specimen that is an indicator of nutritional status with respect to intake or metabolism of dietary constituents is termed as nutritional biomarkers. It can be a biochemical, functional or clinical index of status of an essential nutrient or other dietary constituent. Biomarkers as a means of validation of dietary instruments; surrogate indicators of dietary intake; or combined measures of nutritional status for a nutrient. For a biomarker to be used for validation of a dietary instrument, it should have a strong direct relationship with dietary intakes and be an independent assessment of the dietary intake of the nutrient of interest.

  • Track 9-1: Biomarkers of Oxidative Stress in Blood
  • Track 9-2: Biomarkers in Neonatology and Menopause
  • Track 9-3: Biomarkers for the management of pre-eclampsia in pregnant women
  • Track 9-4: Dietary biomarkers
  • Track 9-5: FDA(Food and Drug Administration)
  • Track 9-6: Urinary Markers in Nutritional Studies

To develop “early warning” indicators at the individual level that can predict population or ecosystem level impacts is the main aim of research of environmental biomarkers. The behavior (or activities) of an organism represent the final integrated result of a diversity of biochemical and physiological processes. Thus, a single evident parameter is generally more extensive than a physiological or biochemical parameter.

  • Track 10-1: Invertebrate populations and communities.
  • Track 10-2: Animal, plant and microbes biomarkers as indictors
  • Track 10-3: Biomarker for Environmental Health
  • Track 10-4: Urinary Biomarkers of Environmental Health
  • Track 10-5: Aquatic population and organic matters as biomarkers

The future application of biomarkers in critical illness will be to select and guide therapy. Selective biomarkers could analyze a pathophysiologic perturbation or noxious mediator to counteract or the need to replete a deficient protective protein. Functional genomics could identify patients at risk for illness or at risk for a poor outcome in critical illness. Genetic expression studies could help differentiate patients with the presence in tissues of harmful bacteria and their toxins from those with noninfectious inflammation and could also help to monitor illnesses over time. Expressional and functional proteomics could lead to the identification of new biomarkers and organ-specific therapies.

  • Track 11-1: Future innovations.
  • Track 11-2: Nano switches
  • Track 11-3: Alternative biomarkers
  • Track 11-4: Future of environmental biomarkers
  • Track 11-5: Biomarkers in Environmental Assessment.
  • Track 11-6: Lifestyle of organisms in response to the environmental change

Current genomics and biotechnology promise the development of biomarkers to predict individual disease risk which enable early detection of disease, and improve diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict risk of disease, to enable early detection of disease, to improve treatment selection and to monitor the outcome of therapeutic interventions. The major objective of the Human Genome Project was the identification and development of such biomarkers for ‘personalized, preventive and predictive medicine.

  • Track 12-1: Current drug therapies
  • Track 12-2: Genomics-based, targeted therapies
  • Track 12-3: Advance genomics
  • Track 12-4: Bionano genomics
  • Track 12-5: Gene expression biomarkers
  • Track 12-6: Interim analysis and selection Biomarkers
  • Track 12-7: Bioinformatics and Computational genomics

An emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.

  • Track 13-1: Pharmacogenetics and pharmacogenomics
  • Track 13-2: Personalized medicine
  • Track 13-3: Stroke genomics
  • Track 13-4: Genomics Protocols

Cardiovascular disease (CVD) involving the heart, brain, and peripheral circulation is the leading cause of death worldwide. Genetics play a role in conferring risk for nearly all CVD disorders. Enormous effort has been undertaken to understand genes responsible for or protected from CVD. Cardiovascular disease encloses a range of conditions extending from myocardial infarction to congenital heart disease most of which are heritable. Immense effort has been invested in understanding the genes and specific DNA sequence variants responsible for this heritability

  • Track 14-1: Genes and Polymorphisms in Cardiovascular Disease
  • Track 14-2: Gene Therapy
  • Track 14-3: Stem Cells and the Cardiovascular System
  • Track 14-4: Other Techniques Regenerative Tissues

One of the major challenges in biology is to connect genotypes to phenotypes and to identify the ecological and demographic parameters that have shaped genotype frequencies in natural populations. Ecological Genomics is an integrative field of study that seeks to understand the genetic mechanisms underlying adaptive responses of organisms to their environment. Biological diversity emerges from the interaction between genomes and their environment. Recent conceptual and technological developments allow dissecting these interactions over short and long time-scales

  • Track 15-1: Natural Selection in genomes
  • Track 15-2: Ecological Differentiation in Microbial Genomes
  • Track 15-3: Phenotypic Plasticity
  • Track 15-4: Ecological Endocrinology
  • Track 15-5: Recent application on ecological genomics

The entire set of nucleic acid sequence of an individual are being encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria is being an advancement in human genomics. Both protein-coding DNA genes and noncoding DNA are included in human genomics. Human Genomics focuses on the application of genomic analysis in all aspects of human health and disease, as well as the genomic analysis of adverse drug reactions, drug efficacy and safety.

  • Track 16-1: Cellular and Molecular Genetics
  • Track 16-2: Genomics: Disease and Evolution
  • Track 16-3: Diabetes and Obesity
  • Track 16-4: Congenital Disorders
  • Track 16-5: Cytogenetics
  • Track 16-6: Transplantation
  • Track 16-7: Neurodevelopmental Disorders
  • Track 16-8: Bioinformatics in Human Genetic

Genomics research holds the key to meeting many of the challenges of the coming years. Now, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.

  • Track 17-1: Genetic epidemiology and pharmacoepidemiology
  • Track 17-2: Genetic counseling
  • Track 17-3: Biomarkers in Genomic Medicine
  • Track 17-4: Phenomics
  • Track 17-5: Synthetic biology and bio-engineering
  • Track 17-6: Transnational genetics and genomics
  • Track 17-7: Genomics in ageing

Next Generation Sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.

  • Track 18-1: Exome sequencing
  • Track 18-2: Hybrid sequencing approach
  • Track 18-3: Sequencing Technologies
  • Track 18-4: Cell and Gene Therapy
  • Track 18-5: NGS Data Analysis
  • Track 18-6: Role of NGS in Cancer Drug Development
  • Track 18-7: Clinical Applications of NGS
  • Track 18-8: Advances of NGS in Therapeutics